Most undervalued micro cap bio-tech. Currently trading under a dime.
The company recently announced a deal with Becton Dickinson to develop its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual revenues.
Last week the company announced "orphan indication" for its MANF drug as a potential treatment for Retinitis Pigmentosa.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's scientific advisory board.
Due diligence before it gaps higher.
Read today's news. Close to a deal with Becton Dickinson.
Bargain at seven cents.
8,489 followers currently.
8,472 followers on Twitter: @Amarantus
Read the recent Yahoo news. Substantially undervalued.
Buy and hold for six months. 500% upside.
A license agreement with Becton Dickinson could move the share price to the .50 range.